Aberrant bcl-2 and bax protein expression related to chemotherapy response in neuroblastoma

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 777-784

  Gallo, Gaia ^a,b,c   Giarnieri, Enrico ^a   Bosco, Sandro ^a   Cappelli, Carlo ^a   Alderisio, Mauro ^a   Giovagnoli, Maria Rosaria ^a   Giordano, Antonio ^b   Vecchione, Aldo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Temple University   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Bax; Bcl 2; Chemotherapy; Immunohistochemistry; Neuroblastoma

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL POPULATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; ETOPOSIDE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME;

EID: 0037236086     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Lutz W, Fulda S, Jeremias I, Debatin KM and Schwab M: MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells. Oncogene 17: 339-346, 1998.
2. Berthold F: Neuroblastoma: Tumor Biology and Therapy. In: Pochedly C (ed). CRC Press, Inc: Boca, Raton, 1990, pp 1-27.
3. Schwab M and Joshi V: Pathology and Genetics of Tumours of the Nervous System. In: Kleihues P, Cavenee WK (eds), 1997, pp 117-123.
4. Lasorella A, Lavarone A and Israel MA: Differentiation of neuroblastoma enhances bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Research 55: 4711-4716, 1995.
5. Anderson DJ: The neural crest cell lineage problem: neuropoiesis? Neuron 3: 1-12, 1989.
6. Molenaar WM, Baker DL, Lee VM and Trojanowski JQ: The neuroendocrine and neural profiles of neuroblastomas, ganglioneuroblastomas, and ganglioneuromas. Am J Pathol 136: 375-382, 1990.
7. Cooper MJ, Hutchins GM and Israel MA: Histogenesis of the human adrenal medulla. An evaluation of the ontogeny of chromaffin and nonchromaffin lineages. Am J Pathol 137: 605-615, 1990.
8. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J and Reed JC: Immunohistochemical analysis of bcl-2, bcl-X, mcl-1, and bax in tumors of central and peripheral nervous system origin. Am J Pathol 150 N 3: 805-814, 1997.
9. Nowell PC: The clonal evolution of tumor cell populations. Science 23: 28, 1976.
10. Williams GT: Programmed cell death: apoptosis and oncogenesis. Cell 65: 1097-1098, 1991.
11. King KL and Cidlowski JA: Cell cycle regulation and apoptosis. Annu Rev Phisiol 60: 601-17, 1998.
12. Dive C and Hickman JA: Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 64: 192-196, 1991.
13. Barry MA, Behnke CA and Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs toxins and hyperthermia. Bioch Pharmacol 40: 2353-2362, 1993.
14. Sen S and D'Incalci M: Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett 307: 122-127, 1992.
15. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
16. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK and Castleberry RP: The international neuroblastoma pathology classification (the Shimada system). Cancer 86: 364-372, 1999.
17. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
18. Yang E and Korsmeyer SJ: Molecular thanatopsis: a discourse on the bcl-2 family and cell death. Blood 88: 386-401, 1996.
19. Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang H-G and Reed JC: Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 91: 9238-9242, 1994.
20. Oltvai ZN and Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes. Cell 79: 189-192, 1994.
21. Yunis JJ, Mayer MG, Arensen MA, Aeppli DP, Okerl MM and Frizzera G: Bcl-2 and other genomic alterations in the prognosis of large-cell lymphomas. N Engl J Med 320: 1047-1054, 1989.
22. Campos L, Roualult J-P, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud J-P and Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 18: 3091-3096, 1993.
23. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM and Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
24. Lombet A, Zujovic V, Kandouz M, Billardon C, Carvajal-Gonzalez S, Gompel A and Rostene W: Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neural differentiation. Role of Bcl-2 protein family. Eur J Biochem 268: 1352-1362, 2001.
25. Hoehner JC, Hedborg F, Jernberg Wiklund H, Olsen L and Pahlman S: Cellular death in neuroblastoma: in situ correlation of apoptosis and bcl-2 expression. Int J Cancer 62: 19-24, 1995.
26. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA and Castle VP: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res.54: 3253-3259, 1994.
27. Weller M, Malipiero U, Aguzzi A and Reed JC: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643, 1995.
28. Hanada M, Krajewski S, Tanaka S, Cazals-H. D, Spengler BA, Ross RA, Biedler JL and Reed JC: Regulation of bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res 53: 4978-4986, 1993.
29. Park SA, Park HJ, Byung IL, Ahn YH, Kim SU and Choi KS: Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERIC-mediated p53 accumulation in B104 cells. Molecular Brain Res 93: 18-26, 2001.
30. McPake CR, Tillman DM, Poquette CA, George EO, Houghton JA and Harris LC: Bax is an important determinant of chemo sensitivity in pediatric tumor cell lines independent of bcl-2 expression and p53 status. Oncol Res 10: 235-244, 1998.
31. Homma A, Furuta Y, Oridate N, Nakano Y, Kohashi G, Yagi K, Nagahashi T, Fukuda S, Inoue K and Inuyama Y: Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 5: 801-806, 1999.
32. Gasparini G, Bevilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P, Boracchi P, Guglielmi RB and Pezzella F: Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1: 1375-1383, 1995.
33. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC and Mason DY: Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690-694, 1993.
34. Fontanini G, Vignati S, Bigini D, Mussi M, Angeletti CA, Basolo F and Bevilacqua G: Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71: 1003-1007, 1995.